• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

遗传性血管性水肿:最新技术综述,III:遗传性血管性水肿的发病机制

Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema.

作者信息

Davis Alvin E

机构信息

CBR Institute for Biomedical Research, Harvard Medical School, Boston, Massachusetts 02115, USA.

出版信息

Ann Allergy Asthma Immunol. 2008 Jan;100(1 Suppl 2):S7-12. doi: 10.1016/s1081-1206(10)60580-7.

DOI:10.1016/s1081-1206(10)60580-7
PMID:18220146
Abstract

OBJECTIVE

To review the available evidence on the pathophysiologic mechanism of episodes of edema in hereditary angioedema (HAE).

DATA SOURCES

MEDLINE and PubMed were searched using the following keywords: hereditary angioedema, C1 inhibitor, complement system, contact system, and bradykinin.

STUDY SELECTION

Studies were selected based on their relevance to the pathophysiologic features of HAE.

RESULTS

Early studies from the 1970s and 1980s disagreed as to whether the symptoms in HAE were mediated via complement or contact system activation. Studies have demonstrated that, in vitro, in C1 inhibitor (C1-INH)-deficient plasma, only contact system activation results in generation of a vascular permeability enhancing factor. Furthermore, individuals who express a variant C1-INH that is a normal inhibitor of contact system proteases but is deficient in the ability to inactivate complement system proteases do not develop angioedema. The blood of patients with HAE, during attacks, contains elevated levels of cleaved high-molecular-weight kininogen and bradykinin. Last, C1-INH-deficient mice develop increased vascular permeability that is mediated via contact system activation.

CONCLUSIONS

Hereditary angioedema attacks are mediated by bradykinin generated via contact system activation. The specific factors that trigger attacks remain unclear.

摘要

目的

综述遗传性血管性水肿(HAE)发作时病理生理机制的现有证据。

资料来源

使用以下关键词检索MEDLINE和PubMed:遗传性血管性水肿、C1抑制物、补体系统、接触系统和缓激肽。

研究选择

根据与HAE病理生理特征的相关性选择研究。

结果

20世纪70年代和80年代的早期研究对于HAE症状是通过补体激活还是接触系统激活介导存在分歧。研究表明,在体外,在缺乏C1抑制物(C1-INH)的血浆中,只有接触系统激活会导致产生一种血管通透性增强因子。此外,表达一种变异型C1-INH的个体,该变异型C1-INH是接触系统蛋白酶的正常抑制剂,但缺乏使补体系统蛋白酶失活的能力,不会发生血管性水肿。HAE患者发作期间的血液中,裂解的高分子量激肽原和缓激肽水平升高。最后,缺乏C1-INH的小鼠会出现通过接触系统激活介导的血管通透性增加。

结论

遗传性血管性水肿发作由接触系统激活产生的缓激肽介导。引发发作的具体因素仍不清楚。

相似文献

1
Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema.遗传性血管性水肿:最新技术综述,III:遗传性血管性水肿的发病机制
Ann Allergy Asthma Immunol. 2008 Jan;100(1 Suppl 2):S7-12. doi: 10.1016/s1081-1206(10)60580-7.
2
Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment.遗传性和获得性C1抑制物依赖性血管性水肿:从病理生理学到治疗
Ann Med. 2016;48(4):256-67. doi: 10.3109/07853890.2016.1162909. Epub 2016 Mar 26.
3
Treatment of episodes of hereditary angioedema with C1 inhibitor: serial assessment of observed abnormalities of the plasma bradykinin-forming pathway and fibrinolysis.遗传性血管性水肿发作的治疗:对血浆缓激肽形成途径和纤溶观察到的异常进行连续评估。
Ann Allergy Asthma Immunol. 2010 Jan;104(1):50-4. doi: 10.1016/j.anai.2009.11.014.
4
High-molecular-weight kininogen cleavage correlates with disease states in the bradykinin-mediated angioedema due to hereditary C1-inhibitor deficiency.在由遗传性C1抑制物缺乏引起的缓激肽介导的血管性水肿中,高分子量激肽原的裂解与疾病状态相关。
Clin Exp Allergy. 2014 Dec;44(12):1503-14. doi: 10.1111/cea.12293.
5
Hereditary angioedema: the plasma contact system out of control.遗传性血管性水肿:失控的血浆接触系统。
J Thromb Haemost. 2018 Sep;16(9):1674-1685. doi: 10.1111/jth.14209. Epub 2018 Jul 17.
6
Hereditary angioedema: Pathophysiology (HAE type I, HAE type II, and HAE nC1-INH).遗传性血管性水肿:病理生理学(HAE 型 I、HAE 型 II 和 HAE nC1-INH)。
Allergy Asthma Proc. 2020 Nov 1;41(Suppl 1):S14-S17. doi: 10.2500/aap.2020.41.200081.
7
Biochemistry, molecular genetics, and clinical aspects of hereditary angioedema with and without C1 inhibitor deficiency.遗传性血管性水肿伴和不伴 C1 抑制剂缺乏症的生化、分子遗传学和临床方面。
Allergol Int. 2023 Jul;72(3):375-384. doi: 10.1016/j.alit.2023.04.004. Epub 2023 May 9.
8
The safety of treatments for angioedema with hereditary C1 inhibitor deficiency.遗传性C1抑制剂缺乏所致血管性水肿治疗的安全性
Expert Opin Drug Saf. 2015;14(11):1725-36. doi: 10.1517/14740338.2015.1094053. Epub 2015 Oct 1.
9
Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels.C1抑制剂水平正常的遗传性血管性水肿患者血浆中纤溶酶原激活物抑制剂2缺乏
J Allergy Clin Immunol. 2016 Jun;137(6):1822-1829.e1. doi: 10.1016/j.jaci.2015.07.041. Epub 2015 Sep 26.
10
sgp120 and the contact system in hereditary angioedema: A diagnostic tool in HAE with normal C1 inhibitor.sgp120 与遗传性血管性水肿中的接触系统:正常 C1 抑制剂的 HAE 中的诊断工具。
Mol Immunol. 2020 Mar;119:27-34. doi: 10.1016/j.molimm.2020.01.003. Epub 2020 Jan 16.

引用本文的文献

1
Erratum: Characteristics and Comorbidities Influencing Mortality Risk Among Hereditary Angioedema Patients.勘误:影响遗传性血管性水肿患者死亡风险的特征及合并症
J Health Econ Outcomes Res. 2025 Aug 21;12(2):143450. doi: 10.36469/001c.143450. eCollection 2025.
2
Throat microbiota alterations in patients with hereditary angioedema.遗传性血管性水肿患者的咽喉微生物群改变
World Allergy Organ J. 2022 Sep 28;15(10):100694. doi: 10.1016/j.waojou.2022.100694. eCollection 2022 Oct.
3
Reviewing clinical considerations and guideline recommendations of C1 inhibitor prophylaxis for hereditary angioedema.
回顾遗传性血管性水肿C1抑制剂预防的临床考量及指南建议。
Clin Transl Allergy. 2022 Jan 18;12(1):e12092. doi: 10.1002/clt2.12092. eCollection 2022 Jan.
4
The Skin in Celiac Disease Patients: The Other Side of the Coin.《乳糜泻患者的皮肤:另一面》。
Medicina (Kaunas). 2019 Sep 9;55(9):578. doi: 10.3390/medicina55090578.
5
Prophylaxis of Acute Attacks with a Novel Short-term Protocol in Hereditary Angioedema Patients Requiring Periodontal Treatment.采用新型短期方案对需要进行牙周治疗的遗传性血管性水肿患者急性发作进行预防。
Oral Health Prev Dent. 2020 Jul 4;18(2):355-361. doi: 10.3290/j.ohpd.a42740.
6
The complement system: an evolution in progress.补体系统:正在进行的进化。
F1000Res. 2016 Dec 12;5:2840. doi: 10.12688/f1000research.10065.1. eCollection 2016.
7
Hereditary Angioedema as a Metabolic Liver Disorder: Novel Therapeutic Options and Prospects for Cure.遗传性血管性水肿作为一种代谢性肝脏疾病:新的治疗选择与治愈前景
Front Immunol. 2016 Nov 30;7:547. doi: 10.3389/fimmu.2016.00547. eCollection 2016.
8
Genetics of Hereditary Angioedema Revisited.遗传性血管性水肿的遗传学再探讨。
Clin Rev Allergy Immunol. 2016 Oct;51(2):170-82. doi: 10.1007/s12016-016-8543-x.
9
Examination of genetic variants involved in generation and biodisposition of kinins in patients with angioedema.血管性水肿患者中激肽生成和生物处置相关遗传变异的检测。
Allergy Asthma Clin Immunol. 2014 Dec 12;10(1):60. doi: 10.1186/s13223-014-0060-y. eCollection 2014.
10
Successful use of daily intravenous infusion of C1 esterase inhibitor concentrate in the treatment of a hereditary angioedema patient with ascites, hypovolemic shock, sepsis, renal and respiratory failure.每日静脉输注C1酯酶抑制剂浓缩物成功用于治疗一名患有腹水、低血容量性休克、败血症、肾和呼吸衰竭的遗传性血管性水肿患者。
Allergy Asthma Clin Immunol. 2014 Dec 11;10(1):62. doi: 10.1186/s13223-014-0062-9. eCollection 2014.